Regenative Labs

Freedom is not and has never been free! Today, we honor all who have served our country. Regenative Labs, in partnership with the Brothers in Arms Foundation, is proud to stand by our nation’s heroes—past and present. Your courage and dedication inspire us every day. Happy Veterans Day! #VeteransDay #HonoringOurHeroes #BrothersInArms #ProudToSupport

❗Published Evaluation of Wharton’s Jelly Allografts for Structural Support in Hip Pathology❗ The study follows 69 patients with hip defects from 26 private practices who received an application of a Wharton’s jelly allograft from Regenative Labs. The overall objective of this study was to evaluate the improvement of patient-reported pain, quality of life, and functionality scales after applying Wharton’s jelly (WJ) in hip defects. The application of Wharton’s jelly allografts was observed to promote decreases in patient reported NPRS scores, pain, and stiffness in the shoulder and improve function. Read the full study here: https://hubs.li/Q02W26b50

Curious about the cutting-edge innovations at Regenative Labs? Get an exclusive behind-the-scenes look at our research labs and see how our team is pushing the boundaries in the field of regenerative through medical and workplace advancement. Want to see our lab in person? Private tours are available by appointment. Contact us today to schedule a time to visit our lab in downtown Pensacola, Florida. https://hubs.ly/Q02SB-TC0 #BehindTheScenes #LabInnovations #RegenerativeMedicine

New legal opinions on the clinical use of Wharton’s jelly from healthcare attorney and former FDA Compliance Officer provide definitive clarity on safety, efficacy, and regulatory compliance. Request copies of both the Product Compliance and the Provider opinion at the bottom of the article below! #regulatoryintelligence #regenerativemedicine

🚀 CEO Update: Steering the Future of Regenerative Medicine at Regenative Labs As part of our ongoing commitment to the field of regenerative medicine, I am pleased to share insights into the strategic directions and new initiatives we are embracing to enhance support in healthcare. New Initiatives Innovative Research: We are deepening our research into the homologues use of Wharton’s Jelly products, focusing on their potential in various applications. Our most recent publications from this year- Wharton’s JELLY TISSUE ALLOGRAFT FOR CONNECTIVE TISSUE DEFECTS SURROUNDING NERVES IN THE TARSAL TUNNEL (https://hubs.li/Q02PHtNz0) and THE SAFETY AND EFFICACY OF Wharton’s JELLY CONNECTIVE TISSUE ALLOGRAFT FOR ROTATOR CUFF TEARS (https://hubs.li/Q02PHqV80) Alignment with Medical Standards: Our development efforts include evaluating how our offerings can be supportive in contexts identifiable by specific ICD-10 medical categories. This methodical approach helps ensure our contributions are relevant and thoughtful. Educational Programs: We are excited to announce upcoming educational initiatives aimed at healthcare professionals. These programs are designed to share knowledge and insights about the foundational science behind our products and their supportive roles in medical practice. We are proud to lead the way in exploring the possibilities of regenerative medicine in pursuit of better patient outcomes. Stay tuned as we continue to innovate responsibly and sustainably. 🔗 #RegenerativeMedicine #HealthcareInnovation #MedicalEducation #Leadership

Regenative Labs had a very successful visit last week sponsoring PAINWeek 2024 in Las Vegas. Our team met numerous physicians, discussing the latest research, sharing insights on clinical applications, and exploring how our high-quality human tissue products can help healthcare providers offer effective, minimally-invasive options for their patients. We look forward to connecting with new and returning contacts as Regenative Labs works to redefine the future of patient care. https://hubs.li/Q02PHqb30

Regenative Labs is excited to announce our participation in PAINWeek 2024, taking place from September 3-6 at The Cosmopolitan in Las Vegas. Our team will be on hand to discuss the latest research, share insights on clinical applications, and explore how our high-quality human tissue products can help healthcare providers offer effective, non-invasive options for their patients. Join us at PAINWeek 2024 to discover how Regenative Labs is redefining the future of patient care. Learn more about PAINWeek: https://hubs.li/Q02NclHZ0

🌟 Achieving Milestones: A Look at Our Key Performance Indicators 🌟 As we continue to innovate in regenerative medicine, we're excited to share our recent achievements and the impact they've had on healthcare. Here's a snapshot of our key performance indicators that underscore our commitment to excellence and innovation: Grafts Distributed: Over 100,000 grafts delivered in 2024, aiding countless patients on their journey to recovery. Adverse Events: Achieved an exceptional record with a 0.0% rate of reported adverse events for our grafts, underscoring our steadfast dedication to maintaining the highest standards of safety and quality. Data Contributions: Nearly 20,000 data entries have been submitted to our retrospective repository. The resultant publication continue to enhance the global understanding of regenerative medicine. Homologous Uses Identified: Discovered 180 new homologous uses for our products, expanding their potential applications in clinical settings. Looking Ahead: Stay tuned for more updates as we push the boundaries of what's possible in regenerative medicine. Thank you to our team and partners for your continued support and dedication to transforming patient care. 🔗 #RegenerativeMedicine #HealthcareInnovation #PatientCare

Happy fourth of July! Regenative Labs and the Brothers in Arms Foundation are proud to support our nation's heroes. #IndependenceDay #SupportOurHeroes #BIAF

Check out this new study on the safety and efficacy of Wharton's Jelly allografts for rotator cuff tears!🏆 Dr. Albert Lai of Desert Pain Specialists and Dr. Conrad Tamea of Orthopedic Associates of Tampa Bay participated in a study showcasing the safety and efficacy of Wharton's Jelly connective tissue allografts for rotator cuff tears. The study titled "Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears," was published by MDPI and can be accessed in its entirety here: https://lnkd.in/eZabw7da "Incorporating Wharton's jelly into our practice has provided an effective conservative option for patients with rotator cuff defects that outperforms conventional therapies. Utilizing the structural connective tissue allografts has allowed many patients to avoid surgery altogether and significantly improve their quality of life," says Dr. Lai. "As a board-certified Orthopedic Surgeon with over 25 years of operative experience, I can say after using Wharton's jelly allografts in more than 200 cases, I have found them to be extremely beneficial to my patients. Orthopedic applications using Wharton's jelly, including in the knee, shoulder, hip, and spine, are more often than not preventing the need for surgery that results in a prolonged recovery time, lost wages, and great financial cost," added Dr. Tamea. #orthopedics #painmanagement #regenerativemedicine